Groupe d'Etude en Oncologie du Quebec

Titre	Tranexamic Acid During Cystectomy Trial (TACT)
Protocole ID	TACT
ClinicalTrials.gov ID	NCT01869413
Type(s) de cancer	Vessie/urothélial
Phase	Phase III
Type étude	Traitement
Médicament	Tranexamic acid
Institution	CHU DE QUEBEC – UNIVERSITE LAVAL L'HOTEL-DIEU DE QUEBEC ET CRCEO 11 Côte du Palais, Québec, QC, G1R 2J6
Ville	Québec
Investigateur(trice) principal(e)	Dr Vincent Fradet
Coordonnateur(trice)	Marilyn Savard 418-525-4444 poste 20414
Statut	Fermé
Critètes d'éligibilité	Participant ≥ 18 years at time of consent Participant has bladder cancer and will undergo radical cystectomy to remove bladder Participant is willing to receive blood products (i.e. packed red blood cells, platelets, plasma) Have obtained Informed Consent
Critètes d'exclusion	Participant declines consent Participants incapable (incompetent) of providing Informed Consent Participant is under 18 years Participant is unwilling to receive blood products due to personal reasons Participant has ever had a pulmonary embolism, deep venous thrombosis, thrombotic stroke, atrial fibrillation, coronary stents or has active angina Participant with known personal history of subarachnoid haemorrhage. Participant has acquired disturbances to his / her colour vision (does not apply to congenital colour blindness) Participant is pregnant (confirmed by βHCG test) Participant has a known allergy to tranexamic acid

Groupe d'étude en oncologie du Québec